Courier Capital LLC reduced its holdings in Johnson & Johnson (NYSE:JNJ) by 3.2% during the third quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 85,515 shares of the company’s stock after selling 2,783 shares during the quarter. Johnson & Johnson comprises 1.5% of Courier Capital LLC’s investment portfolio, making the stock its 13th largest position. Courier Capital LLC’s holdings in Johnson & Johnson were worth $12,165,000 as of its most recent SEC filing.
Several other hedge funds have also modified their holdings of JNJ. Newfound Research LLC bought a new stake in shares of Johnson & Johnson in the 3rd quarter worth approximately $28,000. Islay Capital Management LLC bought a new stake in shares of Johnson & Johnson in the 2nd quarter worth approximately $42,000. FAI Wealth Management boosted its position in shares of Johnson & Johnson by 45.9% during the second quarter. FAI Wealth Management now owns 321 shares of the company’s stock valued at $45,000 after purchasing an additional 101 shares in the last quarter. SeaBridge Investment Advisors LLC boosted its position in shares of Johnson & Johnson by 160.0% during the second quarter. SeaBridge Investment Advisors LLC now owns 325 shares of the company’s stock valued at $46,000 after purchasing an additional 200 shares in the last quarter. Finally, HWG Holdings LP bought a new stake in shares of Johnson & Johnson during the second quarter valued at approximately $49,000. Hedge funds and other institutional investors own 67.44% of the company’s stock.
In other Johnson & Johnson news, EVP Kathryn E. Wengel sold 16,115 shares of the business’s stock in a transaction dated Wednesday, September 2nd. The stock was sold at an average price of $153.52, for a total transaction of $2,473,974.80. Following the completion of the sale, the executive vice president now owns 66,658 shares of the company’s stock, valued at $10,233,336.16. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Insiders own 0.27% of the company’s stock.
Johnson & Johnson (NYSE:JNJ) last posted its quarterly earnings data on Sunday, October 18th. The company reported $2.20 EPS for the quarter, beating analysts’ consensus estimates of $1.98 by $0.22. The company had revenue of $21.08 billion during the quarter, compared to analysts’ expectations of $20.15 billion. Johnson & Johnson had a return on equity of 34.64% and a net margin of 21.01%. Johnson & Johnson’s revenue for the quarter was up 1.7% compared to the same quarter last year. During the same quarter in the prior year, the business earned $2.12 earnings per share. As a group, sell-side analysts predict that Johnson & Johnson will post 7.99 EPS for the current fiscal year.
The business also recently declared a quarterly dividend, which will be paid on Tuesday, December 8th. Shareholders of record on Tuesday, November 24th will be issued a dividend of $1.01 per share. This represents a $4.04 annualized dividend and a yield of 2.76%. The ex-dividend date of this dividend is Monday, November 23rd. Johnson & Johnson’s dividend payout ratio is presently 46.54%.
Several research firms recently weighed in on JNJ. ValuEngine upgraded Johnson & Johnson from a “sell” rating to a “hold” rating in a research report on Monday, August 3rd. Raymond James restated a “buy” rating on shares of Johnson & Johnson in a research report on Friday. Cantor Fitzgerald lifted their price objective on Johnson & Johnson from $168.00 to $180.00 and gave the company an “overweight” rating in a research note on Wednesday, October 14th. Credit Suisse Group lifted their price objective on Johnson & Johnson from $163.00 to $168.00 and gave the company an “outperform” rating in a research note on Wednesday, October 14th. Finally, Stifel Nicolaus cut Johnson & Johnson from a “buy” rating to a “hold” rating in a research note on Wednesday, August 19th. One analyst has rated the stock with a sell rating, four have assigned a hold rating and ten have given a buy rating to the stock. The stock has an average rating of “Buy” and a consensus price target of $164.93.
Johnson & Johnson Company Profile
Johnson & Johnson researches and develops, manufactures, and sells various products in the health care field worldwide. It operates in three segments: Consumer, Pharmaceutical, and Medical Devices. The Consumer segment offers baby care products under the JOHNSON'S brand; oral care products under the LISTERINE brand; beauty products under the AVEENO, CLEAN & CLEAR, DR.
Read More: What’s a Black Swan?
Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ).
Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.